VIAL
Home/Compounds/Rapamycin
MetabolicFDA ApprovedClinical Trials

Rapamycin

About

About Rapamycin

Rapamycin (sirolimus) is an FDA-approved immunosuppressant that is the most robust longevity-extending drug identified in animal models, extending lifespan in mice by 9–14% even when started late in life. It works by inhibiting mTORC1, a central nutrient-sensing pathway. Low-dose, intermittent protocols are being studied and self-administered by longevity researchers for healthspan extension. It carries meaningful immunosuppression risks requiring physician oversight.

Science

Mechanism of Action

Inhibits mechanistic target of rapamycin complex 1 (mTORC1) by forming a complex with FKBP12, reducing protein synthesis, promoting autophagy, and mimicking caloric restriction signaling at the cellular level.

Dosing

Typical Protocol

1–6 mg oral once weekly (longevity protocol); immunosuppression doses are much higher. Requires CBC and metabolic monitoring.

⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.

Regulatory

Legal Status in 2026

FDA Approved

This compound has completed clinical trials and received formal FDA approval for one or more indications. It can be legally prescribed by licensed physicians, filled at any licensed pharmacy, and may be covered by insurance. Off-label use by physicians is also legal. This is the highest level of regulatory clearance available in the US.

Evidence

Evidence Tier

Clinical Trials

Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.

Find a Verified Provider

See which Vial-verified providers offer Rapamycin — with trust scores, legal credentials, and pricing transparency.

Browse all verified providers →